🩸 Reengineering Coagulation: Bridging Factors, Bypassing Factor VIII, Transforming Hemophilia

🩸 Can you replace factor VIII without actually replacing factor VIII? Emicizumab does something more ingenious: this bispecific antibody bridges factor IXa and factor X, functionally recreating a critical role of factor VIIIa. 🔬 After screening ~40,000 candidates, researchers engineered a therapy that enables convenient subcutaneous prophylaxis and works with or without factor VIII inhibitors. 💉 🏆 Recognized with the 2026 Lasker–DeBakey Clinical Medical Research Award, it offers a powerful lesson: sometimes the best way to replace a missing protein is to reengineer its function. 🧬